{"id":520261,"date":"2021-07-29T16:09:03","date_gmt":"2021-07-29T20:09:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"modified":"2021-07-29T16:09:03","modified_gmt":"2021-07-29T20:09:03","slug":"pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","title":{"rendered":"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">REDWOOD CITY, Calif., July  29, 2021  (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41<sup>st<\/sup> Annual Growth Conference on Thursday, August 12, 2021 at 8:30am PT \/ 11:30am ET.<\/p>\n<p align=\"justify\">Interested parties may access a live and archived webcast of the event on the \u201cInvestors\u201d section of the Pulmonx website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=teyEiMg_OMbQiISMcTGUIET_rACY0lbBVkst1F1u6_8XnMYWujv7DMYnL4zVUAhQm_UYfWxb2P01YcmRIxaP85x8rPWjhPK3QY_EQuXgFsTYJiRlyy0e-NNHsD56qqcl\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.pulmonx.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Pulmonx<\/strong><br \/>\n        <br \/>Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment System and StratX\u00ae Lung Analysis Platform are designed to assess and treat patients with severe emphysema\/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a \u201cbreakthrough device.\u201d The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pbQifQ1-4CDzIp36EeFbzTAcVKjaNkynizCwBMaIZfG1-kSOIHrcvVIeksRv88dYLFTwsciGXMK3iW35Usm-6OdK5Q4oicPG7stXJ6eTXVw=\" rel=\"nofollow noopener\" target=\"_blank\">www.MyLungsMyLife.com<\/a>. For more information on the company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CNq8m8jGPbONjk9lv_8zXyv1Q76ZG40mD7XI0jwcc_dzAjq4ADLjuVI3oovEWBD4vEp5AsQLIEyKwmLtQ7BLSw==\" rel=\"nofollow noopener\" target=\"_blank\">www.Pulmonx.com<\/a>.<\/p>\n<p align=\"justify\">Pulmonx\u00ae, Chartis\u00ae, StratX\u00ae, and Zephyr\u00ae are registered trademarks of Pulmonx Corporation.<\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong><br \/>\n        <br \/>Brian Johnston<br \/>Gilmartin Group<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xT48D_YN35qDOjy9PnFpucczSissZdmqqdymRGiqu3Z-2VkLOGfu_A_URBIRYzyxyUYsStqZTueDF9UYkc6wXf1ogP1a7hDAMf7iMJI9chc=\" rel=\"nofollow noopener\" target=\"_blank\">investors@pulmonx.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/574ddabc-f212-4cd5-bb6b-d9ccd635fa43\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8:30am PT \/ 11:30am ET. Interested parties may access a live and archived webcast of the event on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment System and StratX\u00ae Lung Analysis Platform are designed to assess and treat patients with severe emphysema\/COPD who despite &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-520261","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8:30am PT \/ 11:30am ET. Interested parties may access a live and archived webcast of the event on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment System and StratX\u00ae Lung Analysis Platform are designed to assess and treat patients with severe emphysema\/COPD who despite &hellip; Continue reading &quot;Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T20:09:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference\",\"datePublished\":\"2021-07-29T20:09:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"wordCount\":214,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\",\"name\":\"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=\",\"datePublished\":\"2021-07-29T20:09:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","og_description":"REDWOOD CITY, Calif., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8:30am PT \/ 11:30am ET. Interested parties may access a live and archived webcast of the event on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment System and StratX\u00ae Lung Analysis Platform are designed to assess and treat patients with severe emphysema\/COPD who despite &hellip; Continue reading \"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T20:09:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference","datePublished":"2021-07-29T20:09:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"wordCount":214,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","name":"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=","datePublished":"2021-07-29T20:09:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTU2MCM0MzIyNTI2IzIxOTQ1ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=520261"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520261\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=520261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=520261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=520261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}